CD209 and multiminicore myopathy: The patients in high-expression groups for CD163 (TCGA: P = 0.039) (Figure 4A), MMD (TCGA: P = 0.047) (Figure 4B), CSF1 (TCGA: P = 0.013) (Figure 4C), and CD209 (TCGA: P < 0.001) (Figure 4D) showed survival advantages against low-expression groups.